Pengaruh Komorbid Hipertensi terhadap Time Recovery pada Pasien Covid-19 di RSUP Dr. M. Djamil Padang
Abstract
Pendahuluan: COVID-19, merupakan penyakit menular yang disebabkan oleh virus SARS-CoV-2. Tingkat keparahan dan angka kematian COVID-19 dipengaruhi oleh adanya penyakit penyerta yang dimiliki pasien. Penyakit penyerta yang paling banyak ditemukan pada pasien COVID-19 adalah hipertensi, disusul diabetes. Oleh karena itu, untuk menyesuaikan tindakan pengobatan dan pencegahan COVID-19 yang tepat, penting untuk mengetahui faktor prediktor yang berperan dalam proses penyembuhan penyakit ini. Penelitian ini bertujuan untuk mengetahui apakah terdapat pengaruh hipertensi dengan waktu penyembuhan pada pasien COVID-19. Metode: Penelitian ini merupakan penelitian analitik dengan pendekatan cross-sectional. Sebanyak 84 sampel diambil yang dibagi menjadi dua kelompok, yaitu kelompok hipertensi dan non-hipertensi. Data yang diperoleh dari rekam medis terdiri dari data demografi, karakteristik manifestasi klinis dan waktu konversi PCR negatif. Data dianalisis menggunakan Chi-Square Fisher Exact. Hasil: Hasil penelitian menunjukkan bahwa diantara 2 kelompok, kejadian waktu pemulihan yang lama lebih tinggi pada pasien hipertensi (35,7% vs 16,7%). Hasil analisis bivariat antara hipertensi dengan lama kesembuhan adalah p = 0,047 (p < 0,05). Pembahasan: Hasil penelitian ini sejalan dengan beberapa penelitian dimana pada pasien dengan masa pemulihan yang lama, hipertensi merupakan salah satu faktor yang berpengaruh signifikan.
Keywords
Full Text:
PDF (Bahasa Indonesia)References
Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses [Internet]. Vol. 24, Journal of Advanced Research. 2020. p. 91–8. Available from: https://www.sciencedirect.com/science/article/pii/S2090123220300540
Southeast Asia Program. Southeast Asia Covid-19 Tracker [Internet]. Johns Hopkins University and Southeast Asian Health Ministries. 2021 [cited 2021 Jun 28]. Available from: https://www.csis.org/programs/southeast-asia-program/projects/southeast-asia-covid-19-tracker
Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed [Internet]. 2020;91(1):157–60. Available from: https://pubmed.ncbi.nlm.nih.gov/32191675/
Kemkes P. Peta Sebaran COVID 19 INDONESIA [Internet]. INFEKSI EMERGING, Media Informasi Resmi Terkini Penyakit Infeksi Emerging. 2021. Available from: https://infeksiemerging.kemkes.go.id/dashboard/covid-19
Kementrian Kesehatan Republik Indonesia. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MenKes/413/2020 Tentang Pedoman Pencegahan dan Pengendalian Corona Virus Disease 2019 (Covid-19). MenKes/413/2020. 2020;2019:207.
Satuan Tugas Penanganan COVID-19. Peta Sebaran Covid-19. 2021; Available from: https://covid19.go.id/peta-sebaran-covid19
Yuniarti E, Yuniarti E, Hermon D, Dewata I, Barlian E, Iswamdi U, et al. Mapping the High Risk Populations Against Coronavirus Disease 2019 in Padang West Sumatra Indonesia. Int Journals Sci High Technol [Internet]. 2020;20(2):50–8. Available from: https://ijpsat.ijsht-journals.org/index.php/ijpsat/article/view/1754
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet [Internet]. 2020;395(10223):497–506. Available from: https://doi.org/10.1016/S0140-6736(20)30183-5
Guan W-j, Liang W-h, Zhao Y et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;74(10):640.
Huang S, Wang J, Liu F, Liu J, Cao G, Yang C, et al. COVID-19 patients with hypertension have more severe disease: a multicenter retrospective observational study. Hypertens Res [Internet]. 2020;43(8):824–31. Available from:
http://dx.doi.org/10.1038/s41440-020-0485-2
Carlos Enrique Leiva Sisnieguez, Walter Gastón Espeche MRS. Arterial hypertension and the risk of severity and mortality of COVID-19. Eur Respir J. 2020;4(1):1–5.
Kemenkes RI. Hipertensi. Kementrian Kesehat RI [Internet]. 2019;1–5. Available from: https://pusdatin.kemkes.go.id/resources/download/pusdatin/infodatin/infodatin-hipertensi-si-pembunuh-senyap.pdf
Abrahim SA, Tessema M, Defar A, Hussen A, Ejeta E, Demoz G, et al. Time to recovery and its predictors among adults hospitalized with COVID-19: A prospective cohort study in Ethiopia. PLoS One [Internet]. 2020;15(12 December):1–11. Available from: http://dx.doi.org/10.1371/journal.pone.0244269
Wang L, Zhang Y, Cheng Y, Li C, Wang Y, Yan X, et al. Serum triglyceride level and hypertension are highly associated with the recovery of COVID-19 patients. Am J Transl Res. 2020;12(10):6646–54.
Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: A scoping review. Infect Dis Poverty. 2020;9(1):1–12.
Wei CJ, Hu XX, Ye GM, Yang JM. Time and risk factors of viral clearance in COVID-19 patients. Chin Med J (Engl). 2021;134(17):2131–3.
Chen X, Hu MT W, Yang M, Ling J, Zhang Y, Deng L, et al. Risk factors for the delayed viral clearance in COVID-19 patients. J Clin Hypertens. 2021;23(8):1483–9.
Huang X, Wei F, Hu L, Wen L, Chen K. Epidemiology and clinical characteristics of COVID-19. Arch Iran Med [Internet]. 2020;23(4):268–71. Available from: https://doi.org/10.34172/aim.2020.09
Kamyshnyi A, Krynytska I, Matskevych V, Marushchak M, Lushchak O. Arterial hypertension as a risk comorbidity associated with covid-19 pathology. Int J Hypertens. 2020;
Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, et al. Status of hypertension in China: Results from the China hypertension survey, 2012-2015. Circulation. 2018;137(22):2344–56.
SeyedAlinaghi SA, Abbasian L, Solduzian M, Ayoobi Yazdi N, Jafari F, Adibimehr A, et al. Predictors of the prolonged recovery period in COVID-19 patients: a cross-sectional study. Eur J Med Res [Internet]. 2021;26(1):1–10. Available from: https://doi.org/10.1186/s40001-021-00513-x
Xue J, Zheng J, Shang X, Qin E, Zhao P, He Y, et al. Risk factors for prolonged viral clearance in adult patients with COVID-19 in Beijing, China: A prospective observational study. Int Immunopharmacol [Internet]. 2020;89(August):107031. Available from: https://doi.org/10.1016/j.intimp.2020.107031
Hu X, Xing Y, Jia J, Ni W, Liang J, Zhao D, et al. Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19. Sci ofthe Total Environ [Internet]. 2020;(January). Available from: https://doi.org/10.1016/j.scitotenv.2020.138812
Samrah SM, Al-Mistarehi AH, Kewan T, Al-Khatib SM, Ibnian AM, Samrah RS, et al. Viral clearance course of covid-19 outbreaks. J Multidiscip Healthc. 2021;14:555–65.
O’Brien J, Du KY, Peng C. Incidence, clinical features, and outcomes of COVID-19 in Canada: impact of sex and age. J Ovarian Res. 2020;13(1):1–
Goodman KE, Magder LS, Baghdadi JD, Pineles L, Levine AR, Perencevich EN, et al. Impact of Sex and Metabolic Comorbidities on Coronavirus Disease 2019 (COVID-19) Mortality Risk Across Age Groups: 66 646 Inpatients Across 613 U.S. Hospitals. Clin Infect Dis. 2021;73(11):e4113–23.
Pradhan A, Olsson PE. Sex differences in severity and mortality from COVID-19: are males more vulnerable? Biol Sex Differ. 2020;11(1):1–11.
Kwok Leung Ong, Annette W.K. Tso, Karen S.L. Lam BMYC. Gender Difference in Blood Pressure Control and Cardiovascular Risk Factors in Americans With Diagnosed Hypertension [Internet]. [cited 2021 Dec 27]. Available from: http://hyper.ahajournals.org
Chen J, Jiang Q, Xia X, Liu K, Yu Z, Tao W, et al. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation. Aging Cell. 2020;19(7):1–12.
Wang S, Zhang Q, Wang P, Ye H, Jing X, Zhang Z, et al. Clinical features of hypertensive patients with COVID-19 compared with a normotensive group: Single-center experience in China. Open Med. 2021;16(1):367–74.
Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. J Community Empower Heal. 2020;3(2):77.
W. Guan, Z. Ni, Yu Hu et al. Clinical Characteristics of Coronavirus Disease 2019 in China. Vol. 58, The New England Journal of Medicine. 2020. p. 711–2.
Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis [Internet]. 2020;39(6):1011–9. Available from: https://doi.org/10.1007/s10096-020-03874-z
Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: Retrospective case series. BMJ. 2020;368(January):1–7.
Bennasrallah C, Zemni I, Dhouib W, Sriha H, Mezhoud N, Bouslama S, et al. Factors associated with a prolonged negative conversion of viral RNA in patients with COVID-19. Int J Infect Dis [Internet]. 2021;105:463–9. Available from: https://doi.org/10.1016/j.ijid.2021.02.089
Chen X, Hu W, Ling J, Mo P, Zhang Y, Jiang Q, et al. Hypertension and Diabetes Delay the Viral Clearance in COVID-19 Patients. Available from: https://doi.org/10.1101/2020.03.22.20040774
Hoffman EN, Kawachi H, Hirayama A, Zhang J, Murayama A, Masui J, et al. Factors associated with prolonged duration of viral clearance in non-severe SARS-CoV-2 patients in Osaka, Japan. Environ Health Prev Med [Internet]. 2021;26(1):1–11. Available from: https://doi.org/10.1186/s12199-021-01035-y
Trump S, Lukassen S, Anker MS, Chua RL, Liebig J, Thürmann L, et al. Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19. Nat Biotechnol. 2021;39(6):705–16.
DOI: https://doi.org/10.30596/jih.v4i4.17144
Refbacks
- There are currently no refbacks.
Fakultas Kedokteran
Universitas Muhammadiyah Sumatera Utara
Jln.Gedung Arca No. 53 Medan 20217
Telp/HP/Whatsapp: +62 8112570085, +62 857-6248-0974
Website : http://jurnal.umsu.ac.id/index.php/JIH/index
Email : implementahusada@umsu.ac.id